220 related articles for article (PubMed ID: 28012794)
21. Radiation therapy improves disease-specific survival in women with Stage II endometrioid endometrial cancer-Brachytherapy may be sufficient.
Nwachukwu CR; Von-Eyben R; Kidd EA
Brachytherapy; 2018; 17(2):383-391. PubMed ID: 29198879
[TBL] [Abstract][Full Text] [Related]
22. Value of combined adjuvant chemotherapy and radiation on survival for stage III uterine cancer: is less radiation equal to more?
Wang CJ; Christie A; Folkert MR; Xie XJ; Albuquerque K
J Gynecol Oncol; 2018 Jul; 29(4):e49. PubMed ID: 29770620
[TBL] [Abstract][Full Text] [Related]
23. Incorporation of vaginal brachytherapy to external beam radiotherapy in adjuvant therapy for high-risk early-stage cervical cancer: A comparative study.
Ragab OM; Mehta S; Nusbaum DJ; Shimada M; Brunette LL; Roman LD; Matsuo K
Brachytherapy; 2022; 21(2):141-150. PubMed ID: 34756697
[TBL] [Abstract][Full Text] [Related]
24. American Brachytherapy Task Group Report: Adjuvant vaginal brachytherapy for early-stage endometrial cancer: A comprehensive review.
Harkenrider MM; Block AM; Alektiar KM; Gaffney DK; Jones E; Klopp A; Viswanathan AN; Small W
Brachytherapy; 2017; 16(1):95-108. PubMed ID: 27260082
[TBL] [Abstract][Full Text] [Related]
25. Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy.
Wortman BG; Creutzberg CL; Putter H; Jürgenliemk-Schulz IM; Jobsen JJ; Lutgens LCHW; van der Steen-Banasik EM; Mens JWM; Slot A; Kroese MCS; van Triest B; Nijman HW; Stelloo E; Bosse T; de Boer SM; van Putten WLJ; Smit VTHBM; Nout RA;
Br J Cancer; 2018 Oct; 119(9):1067-1074. PubMed ID: 30356126
[TBL] [Abstract][Full Text] [Related]
26. Adjuvant treatment improves overall survival in women with high-intermediate risk early-stage endometrial cancer with lymphovascular space invasion.
Son J; Chambers LM; Carr C; Michener CM; Yao M; Beavis A; Yen TT; Stone RL; Wethington SL; Fader AN; Burkett WC; Richardson DL; Staley AS; Ahn S; Gehrig PA; Torres D; Dowdy SC; Sullivan MW; Modesitt SC; Watson C; Veade A; Ehrisman J; Havrilesky L; Secord AA; Loreen A; Griffin K; Jackson A; Viswanathan A; Ricci S
Int J Gynecol Cancer; 2020 Nov; 30(11):1738-1747. PubMed ID: 32771986
[TBL] [Abstract][Full Text] [Related]
27. Adjuvant Pelvic Radiation Therapy±Vaginal Brachytherapy in Patients With High-risk Stage I or Stage II Uterine Papillary Serous, Clear Cell, and High-grade Endometrioid Carcinoma.
Nagar H; Yan W; Parashar B; Nori D; Chao KS; Christos P; Gupta D; Holcomb K; Caputo T; Wernicke AG
Am J Clin Oncol; 2016 Aug; 39(4):335-9. PubMed ID: 27028349
[TBL] [Abstract][Full Text] [Related]
28. Brachytherapy Improves Survival in Stage III Endometrial Cancer With Cervical Involvement.
Bingham B; Orton A; Boothe D; Stoddard G; Huang YJ; Gaffney DK; Poppe MM
Int J Radiat Oncol Biol Phys; 2017 Apr; 97(5):1040-1050. PubMed ID: 28332987
[TBL] [Abstract][Full Text] [Related]
29. Adjuvant therapy in patients with clear cell endometrial carcinoma: An analysis of the National Cancer Database.
Nieto K; Adams W; Pham N; Block AM; Grover S; Small W; Harkenrider MM
Gynecol Oncol; 2018 Jan; 148(1):147-153. PubMed ID: 29129389
[TBL] [Abstract][Full Text] [Related]
30. National trends, outcomes, and costs of radiation therapy in the management of low- and high-intermediate risk endometrial cancer.
Suidan RS; He W; Sun CC; Zhao H; Smith GL; Klopp AH; Fleming ND; Lu KH; Giordano SH; Meyer LA
Gynecol Oncol; 2019 Mar; 152(3):439-444. PubMed ID: 30876486
[TBL] [Abstract][Full Text] [Related]
31. The role of vaginal brachytherapy in the treatment of surgical stage I papillary serous or clear cell endometrial cancer.
Barney BM; Petersen IA; Mariani A; Dowdy SC; Bakkum-Gamez JN; Haddock MG
Int J Radiat Oncol Biol Phys; 2013 Jan; 85(1):109-15. PubMed ID: 22543202
[TBL] [Abstract][Full Text] [Related]
32. Nomograms for prediction of outcome with or without adjuvant radiation therapy for patients with endometrial cancer: a pooled analysis of PORTEC-1 and PORTEC-2 trials.
Creutzberg CL; van Stiphout RG; Nout RA; Lutgens LC; Jürgenliemk-Schulz IM; Jobsen JJ; Smit VT; Lambin P
Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):530-9. PubMed ID: 25680597
[TBL] [Abstract][Full Text] [Related]
33. Molecular Classification Predicts Response to Radiotherapy in the Randomized PORTEC-1 and PORTEC-2 Trials for Early-Stage Endometrioid Endometrial Cancer.
Horeweg N; Nout RA; Jürgenliemk-Schulz IM; Lutgens LCHW; Jobsen JJ; Haverkort MAD; Mens JWM; Slot A; Wortman BG; de Boer SM; Stelloo E; Verhoeven-Adema KW; Putter H; Smit VTHBM; Bosse T; Creutzberg CL;
J Clin Oncol; 2023 Sep; 41(27):4369-4380. PubMed ID: 37487144
[TBL] [Abstract][Full Text] [Related]
34. Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer--A pooled analysis of PORTEC 1 and 2 trials.
Bosse T; Peters EE; Creutzberg CL; Jürgenliemk-Schulz IM; Jobsen JJ; Mens JW; Lutgens LC; van der Steen-Banasik EM; Smit VT; Nout RA
Eur J Cancer; 2015 Sep; 51(13):1742-50. PubMed ID: 26049688
[TBL] [Abstract][Full Text] [Related]
35. The Effect of Prognostic Factors and Adjuvant Radiotherapy on Survival in Patients with High-Grade Early-Stage Endometrial Cancer: A Retrospective Clinical Study.
Yilmaz E; Gurocak S; Melekoglu R; Koleli I; Faydali S; Temelli O; Yar T
Med Sci Monit; 2019 Apr; 25():2811-2818. PubMed ID: 30992424
[TBL] [Abstract][Full Text] [Related]
36. Factors Predictive of Receiving Adjuvant Radiotherapy in High-Intermediate-Risk Stage I Endometrial Cancer.
McGunigal M; Pollock A; Doucette JT; Liu J; Chadha M; Kalir T; Gupta V
Int J Gynecol Cancer; 2018 Jun; 28(5):882-889. PubMed ID: 29538253
[TBL] [Abstract][Full Text] [Related]
37. External beam radiotherapy versus vaginal brachytherapy in patients with stage II endometrial cancer: a systematic review and meta-analysis.
Narasimhulu DM; Cope A; Riaz IB; Petersen I; Cilby W; Langstraat C; Glaser G; Kumar A; Cappuccio S; Murad MH; West C; Mariani A
Int J Gynecol Cancer; 2020 Jun; 30(6):797-805. PubMed ID: 32221021
[TBL] [Abstract][Full Text] [Related]
38. Predictive factors of recurrence following adjuvant vaginal cuff brachytherapy alone for stage I endometrial cancer.
Dunn EF; Geye H; Platta CS; Gondi V; Rose S; Bradley KA; Anderson BM
Gynecol Oncol; 2014 Jun; 133(3):494-8. PubMed ID: 24657301
[TBL] [Abstract][Full Text] [Related]
39. External radiotherapy versus vaginal brachytherapy for patients with intermediate risk endometrial cancer.
Lin LL; Mutch DG; Rader JS; Powell MA; Grigsby PW
Gynecol Oncol; 2007 Jul; 106(1):215-20. PubMed ID: 17482665
[TBL] [Abstract][Full Text] [Related]
40. The role of vaginal cuff brachytherapy in endometrial cancer.
Harkenrider MM; Block AM; Siddiqui ZA; Small W
Gynecol Oncol; 2015 Feb; 136(2):365-72. PubMed ID: 25555710
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
